Staff

TOP 5 publications:

1. Zimmermann S, Teetzmann A, Baeßler J, Schreckenberger L, Zaiser J, Pfisterer M, Stenger M, Bach P. Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial.Mol Psychiatry. 2025 30(6):2612-2619. Epub 2024 Dec 12.
2. Pfisterer M, Teetzmann A, Vetter S, Baeßler J, Schreckenberger L, Zaiser J, Stenger M, Bach P. CBD attenuates amygdala response to negative emotional stimuli in individuals with alcohol use disorder - a randomized controlled trial.Psychopharmacology (Berl). 2025 Aug 29. [Epub ahead of print].
3. Vetter S, Weinberg J, Thomas BC, Kirchner M, Thalmann P, Klose C, Pfisterer M, Kölsch T, Oesterle S, Vollstädt-Klein S, Koopmann A, Lenz B, Kiefer F, Link T, Bach P. Investigation of the combined effects of cannabidiol plus naltrexone on alcohol craving in alcohol dependence: study protocol of a phase II randomised, double-blind, placebo-controlled, parallel-group trial - ICONICplus Trial.BMJ Open. 2025 15(8):e106348.
4. Pfisterer M, Zimmermann S, Zaiser J, Gerhardt S, Vollstädt-Klein S, Kiefer F, Bach P. Biomarkers in alcohol use disorder - the promise and pitfalls of neuroimaging drug cue reactivityBiomarkers in neuropsychiatry. 2025 12:100119.